Beijing Yaohua Bio-Technology

Beijing Yaohua Bio-Technology is a biopharmaceutical company based in Beijing, China, specializing in the research, development, and manufacturing of recombinant protein therapeutics. Established in 2002, the company has successfully commercialized a portfolio of cytokine-based immunotherapies, including recombinant human interleukin-2 (rhIL-2), granulocyte-macrophage colony-stimulating factor (rhGM-CSF), and interferon alpha-2b. These products, marketed under the "Yao Hua" brand, are primarily used in oncology for treating renal cell carcinoma and melanoma, as well as for managing chemotherapy-induced neutropenia and viral diseases. The company operates GMP-certified manufacturing facilities in the Beijing Economic-Technological Development Area and is recognized as a national high-tech enterprise. Beijing Yaohua Bio-Technology remains focused on leveraging genetic engineering to provide effective immunotherapy solutions for the Chinese market.